נגישות
menu      
Advanced Search
Syntax
Search...
Volcani treasures
About
Terms of use
Manage
Community:
אסיף מאגר המחקר החקלאי
Powered by ClearMash Solutions Ltd -
Thyrotropin-releasing hormone blocks the hypotensive effects of platelet-activating factor in the unanesthetized guinea pig
Year:
1985
Authors :
Ezra, David
;
.
Volume :
7
Co-Authors:
Feuerstein, G., Neurobiology Research Unit, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
Lux, W.E., Jr., Neurobiology Research Unit, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
Ezra, D., Section on Clinical Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
Hayes, E.C., Merck Institute for Therapeutic Research Railway, NJ, United States
Snyder, F., Oak Ridge Associated Universities, Oak Ridge, TN, United States
Faden, A.I., Neurobiology Research Unit, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
Facilitators :
From page:
335
To page:
340
(
Total pages:
6
)
Abstract:
Platelet-activating factor (PAF) and leukotrienes, newly described classes of vasoactive lipids, may play a role in anaphylaxis. It has recently been suggested that the vasoconstrictor effects of PAF in isolated rat lung are related to release of leukotrienes C4 and D4. Thyrotropin-releasing hormone (TRH), a tripeptide, has potent antihypotensive activity in experimental shock, including that resulting from either leukotriene D4 administration or antigen-induced anaphylaxis. We utilized an unanesthetized guinea pig model to study the relationships among PAF, leukotrienes, and TRH and their potential interactions on the cardiovascular system. PAF (1 nmol/600 g body weight i.v.) produced profound hypotension which was completely blocked by TRH (2 mg/kg i.v.). Nafazatrom or FPL 55712, a presumed receptor antagonist of leukotrienes, was ineffective, whereas U-60257, a leukotriene synthesis inhibitor, displayed incomplete blockade. Moreover, leukotriene-like immunoreactivity in plasma did not increase following PAF administration. Thus, hypotension produced by PAF does not appear to result secondarily from release of cysteinyl leukotrienes. Moreover, the ability of TRH to block the hypotensive effects of PAF may partially account for its beneficial effects in experimental anaphylaxis and provides further rationale for the therapeutic evaluation of this peptide in anaphylactic shock. © 1985 Raven Press, New York.
Note:
Related Files :
animal experiment
Animals
Male
protirelin
Show More
Related Content
More details
DOI :
Article number:
Affiliations:
Database:
Scopus
Publication Type:
article
;
.
Language:
English
Editors' remarks:
ID:
29094
Last updated date:
02/03/2022 17:27
Creation date:
17/04/2018 00:44
You may also be interested in
Scientific Publication
Thyrotropin-releasing hormone blocks the hypotensive effects of platelet-activating factor in the unanesthetized guinea pig
7
Feuerstein, G., Neurobiology Research Unit, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
Lux, W.E., Jr., Neurobiology Research Unit, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
Ezra, D., Section on Clinical Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
Hayes, E.C., Merck Institute for Therapeutic Research Railway, NJ, United States
Snyder, F., Oak Ridge Associated Universities, Oak Ridge, TN, United States
Faden, A.I., Neurobiology Research Unit, Uniformed Services University of the Health Sciences, Bethesda, MD, United States
Thyrotropin-releasing hormone blocks the hypotensive effects of platelet-activating factor in the unanesthetized guinea pig
Platelet-activating factor (PAF) and leukotrienes, newly described classes of vasoactive lipids, may play a role in anaphylaxis. It has recently been suggested that the vasoconstrictor effects of PAF in isolated rat lung are related to release of leukotrienes C4 and D4. Thyrotropin-releasing hormone (TRH), a tripeptide, has potent antihypotensive activity in experimental shock, including that resulting from either leukotriene D4 administration or antigen-induced anaphylaxis. We utilized an unanesthetized guinea pig model to study the relationships among PAF, leukotrienes, and TRH and their potential interactions on the cardiovascular system. PAF (1 nmol/600 g body weight i.v.) produced profound hypotension which was completely blocked by TRH (2 mg/kg i.v.). Nafazatrom or FPL 55712, a presumed receptor antagonist of leukotrienes, was ineffective, whereas U-60257, a leukotriene synthesis inhibitor, displayed incomplete blockade. Moreover, leukotriene-like immunoreactivity in plasma did not increase following PAF administration. Thus, hypotension produced by PAF does not appear to result secondarily from release of cysteinyl leukotrienes. Moreover, the ability of TRH to block the hypotensive effects of PAF may partially account for its beneficial effects in experimental anaphylaxis and provides further rationale for the therapeutic evaluation of this peptide in anaphylactic shock. © 1985 Raven Press, New York.
Scientific Publication
You may also be interested in